Docoh
Loading...

71 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs … believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to result in a Material Adverse
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
of individual and corporate objectives; provide for short-term, medium-term and long-term financial and strategic goals; and align the interest … objectives, and the long-term interests of our stockholders, our executive compensation is primarily in the form of equity; to have a portion of each
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
for short-term, medium-term and long-term financial and strategic goals; and align the interest of management with those of the stockholders by providing
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject … clinical trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive AEs and carcinogenicity, may continue after the IND
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
-term use due to the potential risk of myocardial infarction with long-term use. Two clinical studies have been previously conducted by Yuhan
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
to spend more time focusing on our long-term strategic direction and our pipeline,” said Dr. David Young, CEO and Chairman of Processa. “Mike
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
of outstanding options or warrants or conversion of convertible securities), or any material change in the short-term or long-term debt (other than as a result … material change in the short-term or long-term debt of the Company (other than as a result of the conversion of convertible securities), or any
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
is only available through a restricted program for short-term use due to the potential risk of myocardial infarction with long-term use. Two clinical … and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
a restricted program for short-term use due to the potential risk of myocardial infarction with long-term use. Two clinical studies have been previously … , strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
use due to the potential risk of myocardial infarction with long-term use. Two clinical studies have been previously conducted by Yuhan … about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
% of the book value of the assets of the Company (or any license, lease, long-term supply agreement, exchange, mortgage, pledge or other arrangement having … the Long-Term Incentive Plan previously adopted by the Board of Directors and approved by HUWX’s stockholders as currently in effect; “HUWX
S-1/A
EX-10.4
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
in the development for the continuous evaluation of short and long-term strategic financial objectives. ensure credibility of the Accounting and Finance group
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
or conversion of convertible securities), or any material change in the short-term or long-term debt (other than as a result of the conversion of convertible … or long-term debt of the Company (other than as a result of the conversion of convertible securities), or any issuance of options, warrants, convertible
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject … human clinical trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
trials may begin. Some long-term pre-clinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after … are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow up
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
25 Feb 20
Processa Pharmaceuticals Provides Shareholder Update
9:30am
patience and continued support and we look forward to sharing with you the next steps as Processa continues to expand near- and long-term shareholder value